Roflumilast cream (Zoryve®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about Zoryve® for the treatment of atopic dermatitis in patients 6 years of age and older.
You can give input if you are a B.C. resident and have atopic dermatitis, a caregiver to someone with atopic dermatitis, or if your group represents people who live with atopic dermatitis.
If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, November 21, 2025 so that we may submit the questionnaire in time for the deadline.
The submission deadline is November 25, 2025. Patients and caregivers may give their input directly through the link below.
Please click on information sheet link below to learn more about Zoryve® and the questionnaire link below to let BC PharmaCare hear Your Voice:
- To view the information sheet for Zoryve® for the treatment of atopic dermatitis in patients 6 years of age and older: click here
- To complete the Questionnaire as a patient, caregiver, or patient group representative: click here